This segment is dedicated to the research and development of novel therapeutic interventions for Alzheimer's disease, a progressive neurodegenerative disorder affecting millions worldwide. The primary focus is on Simufilam, a proprietary investigational drug designed to restore the normal shape and function of altered filamin A protein in the brain. Research activities involve preclinical studies, Phase 2 and Phase 3 clinical trials, and biomarker analysis to assess drug efficacy and safety. Technologies employed include advanced molecular biology techniques, neuroimaging, and cognitive assessments. The goal is to develop a disease-modifying therapy that can slow or halt the progression of Alzheimer's, improving cognitive function and quality of life for patients. Future opportunities include exploring combination therapies and personalized treatment approaches based on individual patient profiles. Regulatory pathways involve close collaboration with the FDA to ensure compliance and accelerate drug approval.

This segment focuses on the development of innovative diagnostic tools for the early detection and monitoring of neurodegenerative diseases, particularly Alzheimer's disease. The lead diagnostic candidate is SavaDx, a blood-based biomarker assay designed to identify Alzheimer's pathology before significant cognitive decline occurs. Research efforts involve identifying and validating novel biomarkers, developing sensitive and specific detection methods, and conducting clinical studies to assess diagnostic accuracy. Technologies utilized include proteomics, genomics, and advanced data analytics. The aim is to provide clinicians with a reliable and accessible tool for early diagnosis, enabling timely intervention and improved patient outcomes. Market positioning involves establishing SavaDx as a leading diagnostic solution for Alzheimer's, offering a competitive advantage through its non-invasive nature and potential for widespread adoption. Future opportunities include expanding the diagnostic pipeline to cover other neurodegenerative conditions and integrating diagnostic data with therapeutic interventions for personalized medicine.